CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Novo Nordisk Fiscal Q4 2014 Earnings Report | CapyFin

Novo Nordisk

NVO · CSE🇩🇰

Overview Earnings

Dividends Seasonality Metrics

Q1 2026 in 1mo Q4 2025 Q3 2025 -27.77%Q2 2025 -32.83%Q1 2025 +4121.07%Q4 2024 +15.75%Q3 2024 -1.25%Q2 2024 -15.46%Q1 2024 -27.00%Q4 2023 +29.06%Q3 2023 +11.52%Q2 2023 -19.83%Q1 2023 -24.61%Q4 2022 -34.16%Q3 2022 +17.84%Q2 2022 -66.39%Q1 2022 +26.44%Q4 2021 +32.00%Q3 2021 +24.86%Q2 2021 +1.88%Q1 2021 +16.47%Q4 2020 +7.12%Q3 2020 -32.39%Q2 2020 -20.47%Q1 2020 -2.22%Q4 2019 +30.07%Q3 2019 +15.48%Q2 2019 +26.14%Q1 2019 -18.74%Q4 2018 +17.49%Q3 2018 +21.75%Q2 2018 -34.42%Q1 2018 +42.77%Q4 2017 -54.62%Q3 2017 -1.30%Q2 2017 0.00%Q1 2017 +44.66%Q4 2016 -57.82%Q3 2016 -92.69%Q2 2016 -92.36%Q1 2016 -7.55%Q4 2015 +33.49%Q3 2015 -41.05%Q2 2015 -30.57%Q1 2015 +18.94%Q4 2014 -18.49%Q3 2014 +33.46%Q2 2014 -19.36%Q1 2014 +13.50%Q4 2013 +52.00%Q3 2013 +2187.16%

Jan 30, 2015

•

/

Novo Nordisk Q4 2014 Earnings Report

Previous year: DKK 21.8B

Previous year: DKK 1.04

Novo Nordisk

Unlock previous datapoints

Novo Nordisk

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Novo Nordisk